AimedBio’s BI 4060107 Begins Phase 1 Trial Dosing
The first patient has been dosed in the Phase 1 trial of BI 4060107, an antibody-drug conjugate discovered by AimedBio and being developed by Boehringer Ingelheim.
The first patient has been dosed in the Phase 1 trial of BI 4060107, an antibody-drug conjugate discovered by AimedBio and being developed by Boehringer Ingelheim.